电邮这篇文章 Immunopathological aspects in targeted therapy of psoriasis and comorbid conditions.
- 作者: Ardalina O.1
-
隶属关系:
- ФГБОУ ВО Саратовский Государственный медицинский университет им. В.И. Разумовского Минздрава РФ
- 栏目: DERMATOLOGY
- ##submission.dateSubmitted##: 07.04.2025
- ##submission.dateAccepted##: 28.09.2025
- ##submission.datePublished##: 17.11.2025
- URL: https://rjsvd.com/1560-9588/article/view/678188
- DOI: https://doi.org/10.17816/dv678188
- ID: 678188
如何引用文章
全文:
开放存取
##reader.subscriptionAccessGranted##
订阅或者付费存取
详细
Psoriasis is a chronic immune-mediated disease of a multifactorial nature, which has a decisive role in the development of genetic factors. Emerging evidence suggests a central role for IL-17 and IL-23/T17 in the pathogenesis of psoriasis, providing rationale for the use of IL-17 blocking agents as therapeutic agents. Most patients with psoriasis have concomitant comorbid pathology, which is a harbinger of the development of concomitant diseases. This fact must be taken into account when determining patient management tactics and developing new personalized treatment methods. The article provides a review of current literature data on the connection of psoriasis with various comorbid conditions and the key role of IL 17 in targeted therapy.
全文:
作者简介
Oksana Ardalina
ФГБОУ ВО Саратовский Государственный медицинский университет им. В.И. Разумовского Минздрава РФ
编辑信件的主要联系方式.
Email: ardalinaoo@mail.ru
ORCID iD: 0000-0002-9877-1262
SPIN 代码: 6884-0480
ассистент кафедры дерматовенерологии и косметологии СГМУ
俄罗斯联邦, 410028, Saratov, Proviantskaya St., 22, University Clinical Hospital No. 2 (Clinic of Skin and Venereal Diseases)参考
- Олисова О.Ю., Гаранян Л.Г. Эпидемиология, этиопатогенез и коморбидность при псориазе – новые факты. Российский журнал кожных и венерических болезней. 2017; 20(4): 214-219. Olisova O.Yu., Garanyan L.G. Epidemiology, etiopathogenesis and comorbidity in psoriasis – new facts. Russian Journal of Skin and Venereal Diseases. 2017; 20(4): 214-219. [2] Ресурсы и деятельность медицинских организаций дерматовенерологического профиля. Заболеваемость инфекциями, передаваемыми половым путем, заразными кожными болезнями и болезнями кожи в 2023 году: статистические материалы/ И.А.Деев, О.С.Кобякова, А.А.Кубанов и др. Москва: ЦНИИОИЗ Минздрава России, 2024.- 208 с. [3] Рысбекова Д. Е. и др. Корреляционная связь между качеством жизни и тяжестью течения псориаза //Вестник Казахского Национального медицинского университета. – 2020. – №. 1. – С. 75-81. Rysbekova D. Ye. i dr. Korrelyatsionnaya svyaz' mezhdu kachestvom zhizni i tyazhest'yu techeniya psoriaza //Vestnik Kazakhskogo Natsional'nogo meditsinskogo universiteta. – 2020. – №. 1. – S. 75-81. [4] Rendon A., Schäkel K. Psoriasis pathogenesis and treatment //International journal of molecular sciences. – 2019. – Т. 20. – №. 6. – С. 1475. [5] Олисова О.Ю., Гаранян Л.Г. Коморбидности при псориазе. Российский журнал кожных и венерических болезней. 2016; 19(6): 346-348. Olisova O.YU., Garanyan L.G. Komorbidnosti pri psoriaze. Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. 2016; 19(6): 346-348. [6] Рыбалкин С.Б., Агейкин А.В., Агейкина К.А. Особенности выбора генно-инженерных биологических препаратов для лечения псориаза. Эффективная фармакотерапия. 2023; 19 (19): 64–68. Rybalkin S.B., Ageykin A.V., Ageykina K.A. Osobennosti vybora genno-inzhenernykh biologicheskikh preparatov dlya lecheniya psoriaza. Effektivnaya farmakoterapiya. 2023; 19 (19): 64–68. [7] Majumder S., McGeachy M. J. IL-17 in the pathogenesis of disease: good intentions gone awry //Annual review of immunology. – 2021. – Т. 39. – С. 537-556. [8] Соколовский Е. В. Переосмысление успеха терапии: лечение псориаза как системного заболевания //Эффективная фармакотерапия. – 2014. – №. 4. – С. 32. Sokolovskiy Ye. V. Pereosmysleniye uspekha terapii: lecheniye psoriaza kak sistemnogo zabolevaniya //Effektivnaya farmakoterapiya. – 2014. – №. 4. – S. 32. [9] Ion A. et al. Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases //Biology. – 2022. – Т. 11. – No. 6. – С. 808. [10] Bonke, V.-KH. ; Bonke, S. ; Tobin, A.-M. ; Kirbi, B. «Psoriaticheskiy marsh»: kontseptsiya togo, kak tyazhelyy psoriaz mozhet privesti k serdechno-sosudistoy soputstvuyushchemu nasiliyu. Ekspress. Dermatol. 2011, 2020, 303–307. [11] Harper EG, Guo C, Rizzo H, Lillis JV, Kurtz SE, Skorcheva I, Purdy D, Fitch E, Iordanov M, Blauvelt A (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129: 2175–2183. [12] Chiricozzi A, Krueger JG (2013) IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 22:993–1005. [13] Chiricozzi A, Nograles KE, Johnson-Huang LM, Fuentes-Duculan J, Cardinale I, Bonifacio KM, Gulati N, Mitsui H, Guttman-Yassky E, Suárez-Fariñas M, Krueger JG (2014) IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. [14] Belasco J, Louie JS, Gulati N, Wei N, Nograles K, Fuentes-Duculan J, Mitsui H, Suárez-Fariñas M, Krueger JG (2015) Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. Arthritis Rheumatol 67:934–944. [15] Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE (2014) The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 13:496–502. [16] Wang EA, Suzuki E, Maverakis E, Adamopoulos IE (2017) Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol 4:272–277. [17] Miossec P, Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11:763–776. [18] Neymann, A.L. ; Shin, D.B. ; Van, Iks. ; Margolis, DiDzhey ; Troksel', A.B. Gel'fand, Dzh.M. Rasprostranennost' serdechno-sosudistykh faktorov riska u patsiyentov s psoriazom. Dzh. YA. Akad. Dermatol. 20062006, 5555, 829-835. [19] Armstrong, A.V. ; Kharskamp, C.T. ; Armstrong, E.Dzh. Psoriaz i risk sakharnogo diabeta: sistematicheskiy obzor i metaanaliz. DZHAMA Dermatol. 20132013, 149149, 84-91. [20] Armstrong, A.V. ; Kharskamp, C.T. ; Armstrong, E.Dzh. Svyaz' mezhdu psoriazom i gipertoniyey: sistematicheskiy obzor i metaanaliz observatsionnykh issledovaniy. Dzh. Gipertens 2013, 3131, 433. [21] Dreyyer, Dzh. ; Vaytsman, D. ; Davidovovich, B. ; Shapiro, Dzh. ; Koen, A.D. Psoriaz i dislipidemiya: populyatsionnoye issledovaniye. Akta Derm. Venereol. 20082008, 8888, 561-565. [22] Pravenkumar, SSHA ; Ganguli, S. ; Rey, L. ; Nanda, S.K. ; Kuruvila, S. Rasprostranennost' metabolicheskogo sindroma u patsiyentov s psoriazom i yego otnosheniye k prodolzhitel'nosti zabolevaniya: issledovaniye, osnovannoye na bol'nichnom kontrole. Dzh. Klin. Diagnit. Res. 2016, 10, WC01-WC05. [23] Langan, S.M. ; Seminary, N.M. ; Shin, D.B. ; Troksel', A.B. ; Kimmel, S.E. ; Mekhta, N.N. ; Margolis, DiDzhey Gel'fand, Dzh.M. Rasprostranennost' metabolicheskogo sindroma u patsiyentov s psoriazom: populyatsionnoye issledovaniye v Velikobritanii. Dzh. Investiruyte. Dermatol. 2012 god, 132, 556–562. [24] Kimball, A.B. ; Sapari, P. ; Mrovits, U. ; Raykh, K. Lengli, R.G. ; Ty, YU. ; Khsu, MC. ; Usileniye, N. ; Reyder, DiDzhey. ; Mekhta, N.N. Nedostatochnaya diagnostika i nedostatochnaya obrabotka serdechno-sosudistykh faktorov riska u patsiyentov s umerennoy i tyazheloy formoy psoriaza. Dzh. YA. Akad. Dermatol. 2012201267, 67, 76-85. [25] Gaffen, S.L. ; Dzhayn, R. ; Garg, A.V. ; Kua, DiDzhey. Immunnaya os' Il-23-IL-17: ot mekhanizmov do terapevticheskogo testirovaniya. Net. Prepodobnyy. Immunol. 20142014, 1414, 585-600. [26] Sindzho, T. ; Ivashita, M. ; Yamasita, A. ; Sano, T. ; Tsuruta, M. ; Matsunaga, KH. ; Sanui, T. ; Asano, T. ; Nisimura, F. IL-17A sinergeticheski uluchshayet proizvodstvo TNFa-indutsirovannykh IL-6 i CCL20 v adipotsitakh 3T3-L1. Biokhim. Biofy. Res. Kommun. 2016, 477477, 241–246. [27] Yamauti, T. ; Kamon, Dzh. ; Minokoshi, I. ; Ito, YU. ; Vaki, KH. ; Uchida, S. ; Yamasita, S. ; Noda, M. ; Kita, S. ; Ueki, K.; i dr. Adiponetsin stimuliruyet ispol'zovaniye glyukozy i okisleniye zhirnoy kisloty putem aktivatsii AMF-aktivirovannoy AMF-aktivirovannoy proteinkinazy. Net. Med. 20022002, 88, 1288-1295. [28] Фейсханова Л.И., Лапшина С.А. Влияние секукинумаба на развитие дисфункции миокарда у пациентов с анкилозирующим спондилитом. РМЖ. 2020;11:49-53. Feyskhanova L.I., Lapshina S.A. Vliyaniye sekukinumaba na razvitiye disfunktsii miokarda u patsiyentov s ankiloziruyushchim spondilitom. RMZH. 2020;11:49-53. [29] Armstrong, A.V. ; Lin, S.V. ; Chembers, SiDzhey. ; Sokolov, M.Ye. ; Chin, D.L. Psoriaz i tyazhest' gipertonii: rezul'taty issledovaniya sluchay-kontrol'. PLoS ODIN 2011, 66, e18227. [30] Ena, P. ; Madeddu, P. ; Gloriozo, N. ; Tserimele, D. ; Rappelli, A. Vysokaya rasprostranennost' serdechno-sosudistykh zabolevaniy i povyshennaya aktivnost' renin-angiotenzinovoy sistemy u psoriaticheskikh bol'nykh. Akta. Kardiol. 19851985, 4040, 199–205. [31] Salekh, magistr nauk ; Norlander, A.Ye. ; Madkhur, MS. Ingibirovaniye interleykina 17-A, no ne interleykina-17F, signaliziruyushchego o snizhenii arterial'nogo davleniya i snizhenii vospaleniya konechnogo organa pri gipertonii, vyzvannoy angiotenzinom II. Bazovyy perevod JACC. Shitseps. 2016, 11, 606-616. [32] Vu, Dzh. ; Salekh, Magistr ; Kirabo, A. ; Itani, H.A. ; Montaniel, K.R.K. ; Syao, L. ; Chen', W. ; Merno, R.L. ; Tsay, KH. ; Bernstayn, K.Ye.; i dr. Immunnaya aktivatsiya, vyzvannaya okisleniyem sosudov, sposobstvuyet fibrozu i gipertonii. Dzh. Klin. Investiruyte. 2016, 126126, 50-67. [33] Khuan, L.-KH. Zinsel'meyyer, B.KH. ; Chang, K.-KH. ; Sonders, B.T. ; Elvington, A. ; Baba, O. Brokel'mann, Ti Dzhey. ; Tsi, L. ; Ruv, Dzh.S. ; Shvarts, magistr nauk; i dr. Interleykin-17 stimuliruyet interstitsial'noye zatyagivaniye lipoproteinov tkaney v eksperimental'nom psoriaze. Kletochnyy Metab. 2019, 2929, 475-487. [34] Amador, K.A. ; Barriyentos, V. ; Pen'ya, Dzh. ; Errada, A.A. ; Gonsales, M. ; Val'des, S. ; Karrasko, L. ; Al'zamora, R. ; Figeroa, F. ; Kalergis, A.M.; i dr. Spironolakton umen'shayet povrezhdeniye organov, vyzvannoye DOCA, blokiruya aktivatsiyu T-khelpera 17 i snizheniye regulyatsii regulyatornykh T-limfotsitov. Gipertoniya 20142014, 6363, 797–803. [35] Azfar, R.S. Gel'fand, Dzh.M. Psoriaz i metabolicheskiye zabolevaniya: epidemiologiya i patofiziologiya. Kurr. Mneniye. Revmatol. 20082008, 2020, 416-422. [36] Koto-Segura, P. ; Eyris-Sal'vado, N. ; Gonsales-Lara, L. ; Keyro-Silva, R. ; Martines-Kamblor, P. ; Mal'donado-Seral', K. ; Garsiya-Garsiya, B. ; Palasios-Garsiya, L. ; Gomes-Bernal, S. ; Santos-Khuanes, Dzh.; i dr. Psoriaz, psoriaticheskiy artrit i sakharnyy diabet 2 tipa: sistematicheskiy obzor i meta-analiz. Brent Dzh. Dermatol. 20132013, 169169, 783–793. [37] Li, I. ; Lyao, U. ; Chang, M. ; Shrodi, S.Dzh. ; Buy, N. ; Kataneze, Dzhey Dzhey. ; Pun, A. ; Matsunami, N. Kallis-Daffin, K.P. ; Leppert, M.F.; i dr. Dal'neyshiye geneticheskiye dokazatel'stva dlya trekh genov riska psoriaza: ADAM33, CDKAL1 i PTPN22. Dzh. Investiruyte. Dermatol. 20092009, 129129, 629–634. [38] Eyris, N. ; Gonsales-Lara, L. Santos-Khuanes, Dzh. ; Keyro, R. ; Koto, Ye. ; Koto-Segura, P. Geneticheskaya variatsiya pri IL12B, IL23R i IL23A svyazana s tyazhest'yu psoriaza, psoriaticheskim artritom i sakharnym diabetom 2 tipa. Dzh. Dermatol. Shitseps. 20142014, 7575, 167–172. [39] Friis, N.U. ; Khoffmann, N. ; Gildenlov, M. ; Skov, L. ; Vil'sboll', T. ; Nop, F.K. ; Storgordar, KH. Glyukoznyy obmen u patsiyentov s psoriazom. Brent Dzh. Dermatol. 2019, 180180, 264–271. [40] Bonke, S. ; Tachi, D. ; Beshmann, KH. Lyudvig, R.J. ; Akkermann, H. ; Badenkhup, K. ; Beynke, U. KH. U patsiyentov s psoriazom nablyudayutsya priznaki rezistentnosti k insulinu. Brent Dzh. Dermatol. 20072007, 157157, 1249-1251. [41] Maroof A, Smallie T, Archer S, Simpson C, Griffiths M, Baeten D, Shaw S (2017) Dual IL-17A and IL-17F inhibition with bimekizumab provides evidence for IL-17F contribution in immune-mediated inflammatory skin response. J Invest Dermatol 137:S120 [42] Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, vander Heijde D, Landewé R, Nash P, Pricop L, Yuan J, Richards HB, Mpofu S, FUTURE 1 Study Group (2015) Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl JMed 373:1329–1339. [43] Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, Newmark R, Feng J, Erondu N, Nirula A (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 370:2295–2306. [44] Пуиг Л., Бакулев А.Л., Кохан М.М. и др. Эффективность и безопасность нетакимаба, нового моноклонального антитела против IL-17, у пациентов с бляшечным псориазом средней и тяжелой степени. Результаты 54-недельного рандомизированного двойного слепого плацебо-контролируемого клинического исследования PLANETA. Дерматол Тер (Хейдельб) 11, 1319–1332 (2021). Puig, L., Bakulev, A.L., Kokhan, M.M. et al. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb) 11, 1319–1332 (2021).
补充文件
